AEterna Zentaris (TSX:AEZS) EPS (Diluted) : C$-4.60 (TTM As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is AEterna Zentaris EPS (Diluted)?

AEterna Zentaris's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was C$-1.56. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was C$-4.60.

AEterna Zentaris's EPS (Basic) for the three months ended in Dec. 2023 was C$-1.56. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was C$-4.60.

AEterna Zentaris's EPS without NRI for the three months ended in Dec. 2023 was C$-1.66. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was C$-4.70.

During the past 3 years, the average EPS without NRIGrowth Rate was 3.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, AEterna Zentaris's highest 3-Year average EPS without NRI Growth Rate was 70.50% per year. The lowest was -71.90% per year. And the median was 24.40% per year.

AEterna Zentaris EPS (Diluted) Historical Data

The historical data trend for AEterna Zentaris's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEterna Zentaris EPS (Diluted) Chart

AEterna Zentaris Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Diluted)

Get a 7-Day Free Trial

-11.52

-3.98

-2.33

-6.36

-4.58

AEterna Zentaris Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EPS (Diluted)	Get a 7-Day Free Trial															-3.48	-1.20	-0.69	-1.15	-1.56

Competitive Comparison of AEterna Zentaris's EPS (Diluted)

For the Biotechnology subindustry, AEterna Zentaris's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AEterna Zentaris's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AEterna Zentaris's PE Ratio distribution charts can be found below:

* The bar in red indicates where AEterna Zentaris's PE Ratio falls into.

AEterna Zentaris EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

AEterna Zentaris's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-22.206	-	0)	/	4.856
	=	-4.57

AEterna Zentaris's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-7.56	-	0)	/	4.858
	=	-1.56

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-4.60

AEterna Zentaris (TSX:AEZS) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

AEterna Zentaris EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of AEterna Zentaris's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

AEterna Zentaris (TSX:AEZS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (TSX:AEZS) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

AEZS:USA ET8:Germany

Address

222 Bay Street, Suite 3000, PO Box 53, c/o Norton Rose Fulbright Canada, LLP, Toronto, ON, CAN, M5K 1E7

Website

https://www.zentaris.com

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.